Drug intelligence / Profile preview

immune globulin + ganciclovir

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules, Antibody-Based Therapeutics
01

Overview

Immune globulin + ganciclovir is a combination therapy investigated for the treatment of sight-threatening cytomegalovirus (CMV) retinitis, particularly in patients with AIDS. The combination utilizes ganciclovir, a synthetic nucleoside analogue of 2'-deoxyguanosine that inhibits CMV replication by acting as a competitive inhibitor of dGTP incorporation into viral DNA via CMV DNA polymerase. The addition of immune globulin (IVIG) provides passive immunization through a pool of polyvalent IgG antibodies, which can neutralize CMV virions and provide immunomodulatory effects. This specific combination was studied by the American National Red Cross in a pilot trial to determine if it could provide a faster initial response and longer duration of remission compared to ganciclovir monotherapy in immunocompromised individuals.

Other names
immune globulin and ganciclovirIVIG + ganciclovirimmune globulin and ganciclovir combination
02

Targets

CMV DNA polymerase (Human cytomegalovirus DNA polymerase)HCMV surface antigens (Human cytomegalovirus surface antigens)

Beyond the preview

Go deeper on immune globulin + ganciclovir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on immune globulin + ganciclovir.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call